|
Industry: Off-Label Rules Mustn’t Rule Out Public Forum Discussions
The FDA should revise draft off-label guidance to ensure devicemakers can respond immediately to unsolicited questions on off-label uses posed in public forums, industry maintains.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives